Compare Marqeta Inc (MQ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs ResMed Inc. — how do they compare? Marqeta Inc trades at $15.47 (market cap $1.62B), while ResMed Inc. trades at $224.32 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 20.1× Marqeta Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| MQ | RMD | |
|---|---|---|
Market Cap | $1.62B | $32.61B |
Sector | Technology | Health |
52-Week High | $26.00 | $293.73 |
52-Week Low | $15.04 | $182.82 |
Enterprise Value | $935.36M | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $15.6, down 2.26% on the day, with a bearish technical outlook and mixed fundamentals. The stock recently underwent a 4:1 reverse split and shows improving revenue trends, though profitability remains thin. Recent news highlights partnerships with Google and Riskified to expand product offerings and reduce fraud.
The outlook is cautiously optimistic due to revenue growth and strategic expansions, but high valuation ratios and inconsistent earnings pose risks. Analyst consensus is a Buy with a $19 price target, suggesting potential upside if execution improves and margins expand.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
